Financial Performance - Total revenue for Q2 2024 reached €6,305 thousand, a significant increase from €1,205 thousand in Q2 2023, representing a growth of 424%[6] - The operating result for Q2 2024 was a loss of €3,600 thousand, an improvement compared to a loss of €8,811 thousand in Q2 2023, reflecting a reduction in losses by 59%[6] - The total comprehensive income for the six months ended June 30, 2024, was a loss of €10,074 thousand, compared to a loss of €17,044 thousand in the same period of 2023, showing an improvement of 41%[6] - Basic loss per share for Q2 2024 was €(0.03), an improvement from €(0.10) in Q2 2023[6] - For the three months ended June 30, 2024, the net result was a loss of €2,692,000, an improvement from a loss of €7,977,000 in the same period last year, representing a 66.2% reduction in losses[8] Research and Development - Research and development costs for the six months ended June 30, 2024, were €16,331 thousand, up from €11,969 thousand in the same period of 2023, indicating a rise of 36%[6] - Research and development expenditures are reflected in the income statement, with development expenses currently not capitalized due to unmet criteria[22] - Research and development costs for the six-month period ended June 30, 2024, increased to €16,331,000, compared to €11,969,000 for the same period in 2023, reflecting increased outsourced activities and full-time employee equivalents[49] Assets and Liabilities - Total assets decreased to €118,051 thousand as of June 30, 2024, down from €137,883 thousand at the end of 2023, a decline of 14%[3] - Equity attributable to owners of the Company fell to €32,854 thousand at June 30, 2024, down from €41,390 thousand at December 31, 2023, a decrease of 21%[3] - Cash and cash equivalents decreased to €578,970 thousand as of June 30, 2024, from €118,925 thousand at December 31, 2023, indicating a significant reduction in liquidity[3] - Total current liabilities increased to €37,279 thousand as of June 30, 2024, compared to €34,203 thousand at the end of 2023, an increase of 6%[3] - Other current liabilities decreased to €5,675,000 as of June 30, 2024, from €8,509,000 as of December 31, 2023[28] Cash Flow - Cash used in operating activities for the six months ended June 30, 2024, was €22,747,000, compared to cash generated of €33,513,000 in the same period last year, indicating a significant cash outflow[8] - The cash and cash equivalents at the end of the period were €78,970,000, down from €118,925,000 at December 31, 2023, reflecting a decrease of 33.5%[23] - Interest received during the three months ended June 30, 2024, was €610,000, compared to €685,000 in the same period last year, showing a decrease of 10.9%[8] - The company reported a net cash used in investing activities of €267,000 for the three months ended June 30, 2024, compared to €294,000 in the same period last year[8] Income and Grants - The company recognized grant income of €366,000 for the six-month period ended June 30, 2024, compared to €76,000 in the same period of 2023[47] - During the six-month period ended June 30, 2024, the company reached milestones amounting to $4,500,000 (€4,196,000) under its collaboration agreement with Eli Lilly[46] Borrowings and Tax - The company’s total borrowings as of June 30, 2024, amount to €4,437,000, an increase from €4,292,000 as of December 31, 2023[29] - The current income tax liability amounts to € nil as of June 30, 2024, consistent with December 31, 2023[54] - The company has not recognized any deferred tax asset related to operating losses due to uncertainty in future earnings[54] - Tax losses can be carried forward indefinitely, but offset against taxable profit is limited to the first € 1 million, with only 50% of excess profit eligible for offset[54] Company Structure and Operations - The company operates in one reportable segment focused on the discovery and development of innovative RNA-based therapeutics[15] - Amylon Therapeutics B.V., an 80% subsidiary, had convertible loans with an average interest rate of 8% per annum[53] - In the six-month period ended June 30, 2024, the amount of convertible loans and accumulated interest waived was € nil, compared to € 509,000 for the same period in 2023[53] - Amylon was legally dissolved in the third quarter of 2023[53]

The presentation will be available on ProQR's website under Presentations & Publications. Learn more about ProQR at www.proqr.com. Investor contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 skiely@proqr.com or Peter Kelleher LifeSci Advisors T: +1 617 430 7579 pkelleher@lifesciadvisors.com LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announ ...

Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements | Unaudited Condensed Consolidated Statement of Financial Position at March 31, 2024 and December 31, 2023 | PAGE 1 | | --- | --- | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the | | | Three Month Periods ended March 31, 2024 and 2023 | 2 | | Unaudited Condensed Consolidated Statement of Changes in Equity for the Three Month Periods Ende ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Exhibit 99.1 ProQR Announces Year End 2023 Operating and Financial Results LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2024 – ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update. "Over the past year as we exclusively focused our strategy on RNA editi ...

Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements | PAGE | | | --- | --- | | Unaudited Condensed Consolidated Statement of Financial Position at September 30, 2023 and December 31, | | | 2022 | 1 | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the | | | Three and Nine Month Periods ended September 30, 2023 and 2022 | 2 | | Unaudited Condensed Consolidated Statement of Changes in Equity for ...

Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements | Unaudited Condensed Consolidated Statement of Financial Position at June 30, 2023 and December 31, 2022 | PAGE 1 | | --- | --- | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the | | | Three and Six Month Periods ended June 30, 2023 and 2022 | 1 | | Unaudited Condensed Consolidated Statement of Changes in Equity for the Six Month Periods ...

| Unaudited Condensed Consolidated Statement of Financial Position at March 31, 2023 and December 31, 2022 | PAGE 1 | | --- | --- | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the | | | Three Month Periods ended March 31, 2023 and 2022 | 2 | | Unaudited Condensed Consolidated Statement of Changes in Equity for the Three Month Periods Ended March | | | 31, 2023 and 2022 | 3 | | Unaudited Condensed Consolidated Statement of Cash Flows for the Three Month P ...

Financial Reporting and Compliance - The financial statements have been prepared in accordance with IFRS, requiring estimates and assumptions that may affect reported amounts of assets and liabilities [531]. - There have been no material adjustments to prior period estimates for any of the periods included in the Annual Report [531]. - The Company uses non-GAAP financial measures to present its financial position and operating results, which should be used in conjunction with IFRS measures [23]. - The Company maintains its books and records in euro, presenting financial statements in euro as its functional currency [24]. Risks and Uncertainties - Forward-looking statements involve risks and uncertainties, including the impact of the COVID-19 pandemic on operations and clinical trials [30]. - The Company cautions that actual results may differ materially from forward-looking statements due to various risks and uncertainties [32]. - Market data and industry forecasts included in the Annual Report are based on assumptions and limitations, and should not be given undue weight [34]. - The Company relies on contract manufacturers for research and development materials, which poses a risk of supply interruption [30]. Financial Planning and Collaboration - The accuracy of estimates regarding future revenue, expenses, and capital requirements is critical for the Company's financial planning [30]. - The Company emphasizes the importance of securing collaborations with partners to realize intended benefits [30].

Exhibit 99.1 ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event LEIDEN, Netherlands & CAMBRIDGE, Mass., March 29, 2023 – ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced initial pipeline programs focused on diseases that originate in the liver. ProQR will host a virtual R&D event today, during wh ...